Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8001 versus lapatinib + capecitabine in HER2-positive advanced breast cancer
ChiCTR1900027887Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BAT8001 in breast cancer (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-Free Survival. Started Jul 2018; status: recruiting.
02
Drugs
BAT8001
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900027887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027887.